Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction (Version 3: Revised May 20th, 2024).
出版信息
Clin Exp Nephrol. 2025 Feb;29(2):131-133. doi: 10.1007/s10157-024-02607-2. Epub 2025 Jan 3.
Abstract
摘要
相似文献
1
Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction (Version 3: Revised May 20th, 2024).给肾功能不全患者使用钆对比剂的指南（第3版：2024年5月20日修订）
Clin Exp Nephrol. 2025 Feb;29(2):131-133. doi: 10.1007/s10157-024-02607-2. Epub 2025 Jan 3.
2
Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction (version 3: revised may 20th, 2024).给肾功能不全患者使用钆基造影剂的指南（第3版：2024年5月20日修订）
Jpn J Radiol. 2025 May;43(5):717-719. doi: 10.1007/s11604-024-01719-9. Epub 2025 Feb 12.
3
[Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction--second edition].[肾功能不全患者使用钆对比剂的指南——第二版]
Nihon Jinzo Gakkai Shi. 2009;51(7):839-42.
4
[Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction].[给肾功能不全患者使用钆基造影剂的指南]
Nihon Jinzo Gakkai Shi. 2008;50(7):858-60.
5
[Causal relationship between the use of gadolinium based contrast media and nephrogenic systemic fibrosis].钆基造影剂的使用与肾源性系统性纤维化之间的因果关系
Rev Med Chil. 2014 Dec;142(12):1565-74. doi: 10.4067/S0034-98872014001200010.
6
[Korean Clinical Practice Guidelines for Adverse Reactions to Intravenous Iodinate and MRI-Gadolinium Contrast Agents: Revised Clinical Consensus and Recommendations (3rd Edition, 2022)].[《韩国静脉注射碘造影剂和磁共振成像钆造影剂不良反应临床实践指南：修订后的临床共识与建议（2022年第3版）》]
Taehan Yongsang Uihakhoe Chi. 2022 Mar;83(2):254-264. doi: 10.3348/jksr.2022.0024. Epub 2022 Mar 28.
7
High Levels of Gadolinium Deposition in the Skin of a Patient With Normal Renal Function.肾功能正常患者皮肤内钆沉积水平升高。
Invest Radiol. 2016 May;51(5):280-9. doi: 10.1097/RLI.0000000000000266.
8
Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention.基于钆的对比剂：从急性不良反应、肾源性系统性纤维化和脑部蓄积中得到的认识。
Rofo. 2021 Sep;193(9):1010-1018. doi: 10.1055/a-1328-3177. Epub 2020 Dec 21.
9
Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis.钆基磁共振成像造影剂与肾源性系统性纤维化的关联
J Urol. 2008 Sep;180(3):830-5; discussion 835. doi: 10.1016/j.juro.2008.05.005. Epub 2008 Jul 17.
10
Gadolinium-based contrast agents - what is the evidence for 'gadolinium deposition disease' and the use of chelation therapy?镧系元素类对比剂——“镧系元素沉积病”的证据和螯合疗法的应用是什么？
Clin Toxicol (Phila). 2020 Mar;58(3):151-160. doi: 10.1080/15563650.2019.1681442. Epub 2019 Oct 30.
本文引用的文献
1
Waiting times between examinations with intravascularly administered contrast media: a review of contrast media pharmacokinetics and updated ESUR Contrast Media Safety Committee guidelines.血管内应用对比剂的检查间隔时间：对比剂药代动力学回顾及更新的 ESUR 对比剂安全委员会指南。
Eur Radiol. 2024 Apr;34(4):2512-2523. doi: 10.1007/s00330-023-10085-5. Epub 2023 Oct 12.
2
No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid.未发现钆塞酸葡胺给药后发生肾源性系统纤维化病例。
Radiology. 2020 Dec;297(3):556-562. doi: 10.1148/radiol.2020200788. Epub 2020 Sep 29.
3
Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment.在接受肾脏替代治疗的患者中，使用钆特酸给药后的肾源性系统性纤维化发生率。
Magn Reson Imaging. 2020 Jul;70:1-4. doi: 10.1016/j.mri.2020.02.012. Epub 2020 Feb 26.
4
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.接受 II 类钆基造影剂的 4 或 5 期慢性肾脏病患者发生肾源性系统纤维化的风险：系统评价和荟萃分析。
JAMA Intern Med. 2020 Feb 1;180(2):223-230. doi: 10.1001/jamainternmed.2019.5284.
5
A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis.经活检证实的 639 例肾源性系统性纤维化患者的系统评价。
Radiology. 2019 Aug;292(2):376-386. doi: 10.1148/radiol.2019182916. Epub 2019 Jul 2.
6
Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan.钆布醇用于日本对比增强磁共振成像的上市后监测。
Jpn J Radiol. 2018 Nov;36(11):676-685. doi: 10.1007/s11604-018-0778-4. Epub 2018 Sep 19.
7
Gadobutrol in Renally Impaired Patients: Results of the GRIP Study.钆布醇用于肾功能受损患者：GRIP研究结果
Invest Radiol. 2017 Jan;52(1):55-60. doi: 10.1097/RLI.0000000000000307.
8
Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study.钆基对比剂增强磁共振成像后行透析治疗患者的肾源性系统性纤维化发生率：前瞻性肾源性系统性纤维化研究。
Invest Radiol. 2014 Feb;49(2):109-15. doi: 10.1097/RLI.0000000000000000.
Zotero 插件